R&D channel feed – Endpoints News

R&D channel feed

Another ADHD failure cements Aevi's penny stock status

7 years ago

Sanofi walks away from MyoKardia heart drug partnership, long before key data readout

7 years ago

Little Capricor hits the brakes on a stem cell trial for Duchenne MD following an allergic reaction

7 years ago

Pfizer, Merck KGaA hit the brakes on another PhIII as PD-L1 Bavencio flops yet again

7 years ago

Boehringer offloads an mTOR cancer drug as Xynomic plots a quick advance in the clinic

7 years ago

On the heels of China approval, FibroGen and AstraZeneca spotlight more positive PhIII data for roxadustat

7 years ago

Merck KGaA hands off its CAR-T R&D operations to Intrexon in $175M deal

7 years ago

As with children studies, Supernus ADHD drug shows fast onset of action in adolescents

7 years ago

After abruptly pulling its marketing application, DBV may be left with peanuts in race against Aimmune

7 years ago

That’s gotta hurt. FDA turns thumbs down on Spectrum’s 'breakthrough' pitch for cancer drug poziotinib and shares tumble

7 years ago

Gilead dangles $105M in quick cash to sign Scholar Rock to a discovery deal for its growing NASH pipeline

7 years ago

Roche, Alexion ripe for showdown in a race to treat rare CNS disorder

7 years ago

Aiming to shed last-place rep, Eli Lilly touts its PhIII pipeline and promises a faster game in R&D

7 years ago

Surface Oncology reins back its lead program after tracking low-dose toxicity for CD47 drug

7 years ago

Second dose of Sophiris' prostate cancer drug proves futile, shares crash

7 years ago

Broadening its oncology focus, Innovent adds three Incyte drugs to portfolio for $40M cash

7 years ago

Plowing ahead after its latest setback, Axovant nabs two assets to beef up gene therapy pipeline

7 years ago

AstraZeneca wants a do-over on MYSTIC combo data. But a changeup in focus won’t end the death watch on this pairing

7 years ago

Biogen shrugs off $1B-plus gene therapy pact after PhI/II implosion — AGTC shares crater

7 years ago

A new analysis spotlights the top 20 drugs in the late-stage pipeline

7 years ago

Mallinckrodt's woes persist as reformulated opioid painkiller fails to pass FDA muster

7 years ago

In a repeat setback, Neurocrine flags a failure for Tourette syndrome study — shares sink

7 years ago

J&J beats Novartis' blockbuster rival in a head-to-head showdown over the psoriasis market

7 years ago

Too much success? A booming biotech pipeline will spur intense rivalries — analyst

7 years ago

First page Previous page 256 257 258259260 261 262 Next page Last page